Michael Alfieri - Aldeyra Principal Officer
| ALDX Stock | USD 4.85 0.04 0.83% |
Executive
Michael Alfieri is Principal Officer of Aldeyra
| Age | 59 |
| Address | 131 Hartwell Avenue, Lexington, MA, United States, 02421 |
| Phone | 781 761 4904 |
| Web | https://www.aldeyra.com |
Michael Alfieri Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Alfieri against Aldeyra stock is an integral part of due diligence when investing in Aldeyra. Michael Alfieri insider activity provides valuable insight into whether Aldeyra is net buyers or sellers over its current business cycle. Note, Aldeyra insiders must abide by specific rules, including filing SEC forms every time they buy or sell Aldeyra'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Alfieri over two months ago Insider Trading |
Aldeyra Management Efficiency
The company has return on total asset (ROA) of (0.2345) % which means that it has lost $0.2345 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4305) %, meaning that it created substantial loss on money invested by shareholders. Aldeyra's management efficiency ratios could be used to measure how well Aldeyra manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.27 in 2024. Return On Capital Employed is likely to drop to -0.36 in 2024. At this time, Aldeyra's Non Currrent Assets Other are fairly stable compared to the past year. Other Assets is likely to rise to about 5.4 M in 2024, whereas Total Assets are likely to drop slightly above 78.6 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Matthew Beck | Hookipa Pharma | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Christina MBA | Blueprint Medicines Corp | 48 | |
| Lisa DeFrancesco | Lexicon Pharmaceuticals | 45 | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| Ronan JD | Lyra Therapeutics | 51 | |
| Vineeta Belanger | Lyra Therapeutics | N/A | |
| Yun Bai | 89bio Inc | N/A | |
| Yingli Ma | Structure Therapeutics American | 50 | |
| Ray Knox | Lyra Therapeutics | N/A | |
| Shiva CPA | 89bio Inc | 58 | |
| Matthew MBA | Tarsus Pharmaceuticals | 46 | |
| Kathryn Haviland | Blueprint Medicines Corp | 48 | |
| JD Esq | Seres Therapeutics | 69 | |
| Robert Richard | Lyra Therapeutics | 66 | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Melissa Manno | Viridian Therapeutics | N/A | |
| Michael Szumera | Hookipa Pharma | N/A | |
| Lauren MBA | Day One Biopharmaceuticals | 48 | |
| Paul Cocja | Phathom Pharmaceuticals | N/A | |
| Wendy McDermott | Lexicon Pharmaceuticals | 53 | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.23 |
Aldeyra Leadership Team
Elected by the shareholders, the Aldeyra's board of directors comprises two types of representatives: Aldeyra inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aldeyra. The board's role is to monitor Aldeyra's management team and ensure that shareholders' interests are well served. Aldeyra's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aldeyra's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Burke, Head Relations | ||
| Michael Alfieri, Principal Officer | ||
| Kelly Mizer, Vice Operations | ||
| Stephen Machatha, Senior Vice President - Technical Operations | ||
| Laura Nichols, Operations Manager |
Aldeyra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aldeyra a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 191.68 M | ||||
| Shares Outstanding | 59.55 M | ||||
| Shares Owned By Insiders | 2.44 % | ||||
| Shares Owned By Institutions | 62.22 % | ||||
| Number Of Shares Shorted | 3.67 M | ||||
| Price To Earning | (4.44) X | ||||
| Price To Book | 3.39 X | ||||
| EBITDA | (35.21 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Aldeyra Stock Analysis
When running Aldeyra's price analysis, check to measure Aldeyra's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aldeyra is operating at the current time. Most of Aldeyra's value examination focuses on studying past and present price action to predict the probability of Aldeyra's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aldeyra's price. Additionally, you may evaluate how the addition of Aldeyra to your portfolios can decrease your overall portfolio volatility.